{"prompt": "['8.5', 'FINANCIAL DISCLOSURE', 'Investigators will provide the Sponsor with sufficient, accurate financial information in', 'accordance with local regulations to allow the Sponsor to submit complete and accurate', 'financial certification or disclosure statements to the appropriate health authorities.', 'Investigators are responsible for providing information on financial interests during the', 'course of the study and for 1 year after completion of the study (i.e., LPLV).', '9.', 'STUDY DOCUMENTATION, MONITORING, AND ADMINISTRATION', '9.1', 'STUDY DOCUMENTATION', 'The investigator must maintain adequate and accurate records to enable the conduct of the', 'study to be fully documented, including, but not limited to, the protocol, protocol', 'amendments, Informed Consent Forms, and documentation of IRB/EC and governmental', 'approval. In addition, at the end of the study, the investigator will receive the patient data,', 'including an audit trail containing a complete record of all changes to data.', '9.2', 'PROTOCOL DEVIATIONS', 'The investigator should document and explain any protocol deviations. The investigator', 'should promptly report any deviations that might have an impact on patient safety and data', 'integrity to the Sponsor and to the IRB/EC in accordance with established IRB/EC policies', 'and procedures. The Sponsor will review all protocol deviations and assess whether any', 'represent a serious breach of Good Clinical Practice guidelines and require reporting to', \"health authorities. As per the Sponsor's standard operating procedures, prospective\", 'requests to deviate from the protocol, including requests to waive protocol eligibility criteria,', 'are not allowed.', '9.3', 'SITE INSPECTIONS', 'Site visits will be conducted by the Sponsor or an authorized representative for inspection of', \"study data, subjects' medical records, and eCRFs. The investigator will permit national and\", 'local health authorities; Sponsor monitors, representatives, and collaborators; and the', 'IRBs/ECs to inspect facilities and records relevant to this study.', '9.4', 'ADMINISTRATIVE STRUCTURE', 'The IxRS system will be used to confirm the shipment condition and content of the IMP (see', 'Section 0). A central laboratory will be used to conduct all laboratory assessments (see', 'Section 0). A CRO will be responsible for data management of this trial (see Section 7.1). An', 'iDMC will review the safety, efficacy, immunogenicity, and PK data collected during the', 'study (see Section 0). The procedures that will be used by the iDMC will be detailed in an', 'iDMC charter.', '9.4.1', 'Independent Data Monitoring Committee', 'An iDMC will be assembled to review the safety data collected during the study. The iDMC', 'members will consist of, at minimum, independent hemostasis/thrombosis experts and a', 'statistician, none of whom will be otherwise involved in the conduct of study. All analyses for', 'review by the iDMC will be prepared by the SMT statistician. Monitoring and analysis of all', 'Emicizumab - F. Hoffmann-La Roche Ltd', '151 / Protocol MO39129, Version 3']['significant safety events will be performed on a continuous basis. A first interim analysis of', 'the study data will be performed once approximately 100 patients have received treatment', 'with emicizumab for at least 24 weeks (see Section 0), and a second interim analysis will be', 'performed when approximately 100 patients have received treatment with emicizumab for at', 'least 52 weeks. Thereafter, the iDMC will meet at a frequency determined by the iDMC and', 'the Sponsor according to the emerging data.', 'The SMT statistician will perform analyses and provide tables and listings to support the', 'study reviews by the iDMC. The safety data that will be provided will include demographic', 'data, adverse events (the incidence and severity of all adverse events, including', 'thromboembolic events, microangiopathic hemolytic anemia or TMA, systemic hypersensitivity,', 'anaphylaxis, and anaphylactoid events), medication dose information, physical examination', 'findings, vital sign data, and laboratory abnormalities (hematology and chemistry). If', 'available, the efficacy data that will provided will include the number of bleeds over time,', 'ABR data, the HRQoL of patients, the health status of patients according to EQ-5D-5L', 'scores, and patient preference for the emicizumab regimen compared with the previous', 'regimen used. Further information will be provided on request.', 'Following each meeting, the iDMC will recommend to the Sponsor whether the study should', 'continue according to the protocol or may suggest changes to the protocol based on the', 'outcome of the data review. In exceptional cases, the iDMC may recommend stopping the', 'study for safety reasons.', 'The meeting schedule and all other DDC-related activities will be specified in a separate', 'iDMC charter. All closed meetings will be summarized in written minutes available only to', 'iDMC members. These minutes will be kept by the iDMC chair until the end of the study. The', 'recommendations can be communicated to the Sponsor verbally but have to be confirmed in', 'writing according to a pre-defined timeframe.', 'The final decision of acting upon the recommendations from the iDMC will rest with the', 'Sponsor.', '9.5', 'PUBLICATION OF DATA AND PROTECTION OF TRADE SECRETS', 'Regardless of the outcome of a trial, the Sponsor is dedicated to openly providing', 'information on the trial to healthcare professionals and to the public, both at scientific', 'congresses and in peer-reviewed journals. The Sponsor will comply with all requirements for', 'publication of study results. For more information, refer to the Roche Global Policy on', 'Sharing of Clinical Study Information.', 'The results of this study may be published or presented at scientific congresses. For all', 'clinical trials in patients involving an IMP for which a marketing authorization application has', 'been filed or approved in any country, the Sponsor aims to submit a journal manuscript', 'reporting primary clinical trial results within 6 months after the availability of the respective', 'Clinical Study Report. In addition, for all clinical trials in patients involving an IMP for which a', 'marketing authorization application has been filed or approved in any country, the Sponsor', 'aims to publish results from analyses of additional endpoints and exploratory data that are', 'clinically meaningful and statistically sound.', 'Emicizumab - F. Hoffmann-La Roche Ltd', '152 / Protocol MO39129, Version 3']\n\n###\n\n", "completion": "END"}